Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN)

This paper describes the design and baseline characteristics of a phase 3 randomized trial testing once-weekly subcutaneous survodutide (3.6 mg or 4.8 mg) versus placebo, plus lifestyle intervention, in 306 Chinese adults with overweight or obesity. No efficacy or safety results are reported yet. At baseline, participants averaged a BMI of 33.2 kg/m² and 72.9% had at least one obesity-related complication.

Journal article — randomized double-blind placebo-controlled phase 3 trial. Population: Chinese adults with overweight or obesity, eligible if BMI ≥28 kg/m² or BMI ≥24 kg/m² with at least one obesity-related complication. Sample size: 306 Chinese adults. Follow-up: 76 weeks. Interventions: survodutide 3.6 mg once-weekly subcutaneous plus lifestyle intervention; survodutide 4.8 mg once-weekly subcutaneous plus lifestyle intervention.

At baseline, the 306 participants had a mean age of 36.9 years, body weight 93.9 kg, waist circumference 105.6 cm, BMI 33.2 kg/m², and triglycerides 2.2 mmol/L; 49% were women. 72.9% had at least one obesity-related complication, most commonly metabolic dysfunction-associated steatotic liver disease (48.4%), dyslipidemia (42.2%), hypertension (27.8%), and type 2 diabetes mellitus (16.7%). 19.6% had prediabetes, and 4.6% had obstructive sleep apnea and 4.2% had cardiovascular diseases. The abstract reports baseline data only and no post-baseline efficacy or safety results.

For researchers working on survodutide, this paper defines the design and baseline profile of a dedicated phase 3 trial in Chinese adults with overweight or obesity, including the two doses tested and the primary weight-loss endpoints. It does not establish whether survodutide is effective or safe in this population, and it contains no post-baseline outcomes.

Key findings

• The trial randomized 306 Chinese adults with overweight or obesity 1:1:1 to once-weekly subcutaneous survodutide 3.6 mg, survodutide 4.8 mg, or placebo, all plus lifestyle intervention.
• At baseline, mean age was 36.9 years, mean body weight was 93.9 kg, mean waist circumference was 105.6 cm, mean BMI was 33.2 kg/m², and mean triglycerides were 2.2 mmol/L.
• 49% of participants were women.
• 72.9% had at least one obesity-related complication, with metabolic dysfunction-associated steatotic liver disease (48.4%), dyslipidemia (42.2%), hypertension (27.8%), and type 2 diabetes mellitus (16.7%) being the most prevalent.
• 19.6% had prediabetes, while obstructive sleep apnea was present in 4.6% and cardiovascular diseases in 4.2%.
• The primary endpoints were percentage change in body weight and achievement of body weight reduction of at least 5% from baseline to week 52.

Limitations

• The abstract reports only trial design and baseline characteristics, with no efficacy or safety outcomes yet available.
• Eligibility was restricted to Chinese adults with specific BMI thresholds, so findings may not generalize to other populations.
• The primary endpoint is assessed at week 52 within a 76-week trial, so longer-term durability beyond week 52 is not addressed in this abstract.

The record

• Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
• Published: 2026-08-14
• PMID: 42599381 — DOI: 10.1007/s13300-026-01908-x
• Author countries: China, Germany

Peptide profiles: Survodutide.

All indexed evidence: Survodutide trials & papers.

Related studies: Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell…, Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver…, Survodutide Once Weekly for the Treatment of Adults with Obesity, Author Correction: Survodutide in adults with obesity and metabolic….